These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34965434)

  • 1. MAL2 mediates the formation of stable HER2 signaling complexes within lipid raft-rich membrane protrusions in breast cancer cells.
    Jeong J; Shin JH; Li W; Hong JY; Lim J; Hwang JY; Chung JJ; Yan Q; Liu Y; Choi J; Wysolmerski J
    Cell Rep; 2021 Dec; 37(13):110160. PubMed ID: 34965434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The scaffolding protein NHERF1 regulates the stability and activity of the tyrosine kinase HER2.
    Jeong J; VanHouten JN; Kim W; Dann P; Sullivan C; Choi J; Sneddon WB; Friedman PA; Wysolmerski JJ
    J Biol Chem; 2017 Apr; 292(16):6555-6568. PubMed ID: 28235801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells.
    Jeong J; Choi J; Kim W; Dann P; Takyar F; Gefter JV; Friedman PA; Wysolmerski JJ
    J Biol Chem; 2019 Jan; 294(3):887-901. PubMed ID: 30463939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 signaling regulates HER2 localization and membrane retention.
    Jeong J; Kim W; Kim LK; VanHouten J; Wysolmerski JJ
    PLoS One; 2017; 12(4):e0174849. PubMed ID: 28369073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer.
    Jeong J; VanHouten JN; Dann P; Kim W; Sullivan C; Yu H; Liotta L; Espina V; Stern DF; Friedman PA; Wysolmerski JJ
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E282-90. PubMed ID: 26729871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
    Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
    Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential association of the Na+/H+ Exchanger Regulatory Factor (NHERF) family of adaptor proteins with the raft- and the non-raft brush border membrane fractions of NHE3.
    Sultan A; Luo M; Yu Q; Riederer B; Xia W; Chen M; Lissner S; Gessner JE; Donowitz M; Yun CC; deJonge H; Lamprecht G; Seidler U
    Cell Physiol Biochem; 2013; 32(5):1386-402. PubMed ID: 24297041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproliferative effects of γ-tocotrienol are associated with lipid raft disruption in HER2-positive human breast cancer cells.
    Alawin OA; Ahmed RA; Ibrahim BA; Briski KP; Sylvester PW
    J Nutr Biochem; 2016 Jan; 27():266-77. PubMed ID: 26507543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2.
    Nagy P; Vereb G; Sebestyén Z; Horváth G; Lockett SJ; Damjanovich S; Park JW; Jovin TM; Szöllosi J
    J Cell Sci; 2002 Nov; 115(Pt 22):4251-62. PubMed ID: 12376557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.
    Zazo S; González-Alonso P; Martín-Aparicio E; Chamizo C; Luque M; Sanz-Álvarez M; Mínguez P; Gómez-López G; Cristóbal I; Caramés C; García-Foncillas J; Eroles P; Lluch A; Arpí O; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
    Mol Cancer Ther; 2020 Aug; 19(8):1696-1707. PubMed ID: 32404410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.
    Paris L; Cecchetti S; Spadaro F; Abalsamo L; Lugini L; Pisanu ME; Iorio E; Natali PG; Ramoni C; Podo F
    Breast Cancer Res; 2010; 12(3):R27. PubMed ID: 20462431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
    Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D
    Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer.
    Hori A; Shimoda M; Naoi Y; Kagara N; Tanei T; Miyake T; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res; 2019 Aug; 21(1):88. PubMed ID: 31387614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
    Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
    Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
    Chung WP; Huang WL; Liao WA; Huang WL; Liu YY; Su WC
    Cancer Med; 2021 Apr; 10(7):2370-2379. PubMed ID: 33665980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
    Gardaneh M; Shojaei S; Kaviani A; Behnam B
    Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid raft association restricts CD44-ezrin interaction and promotion of breast cancer cell migration.
    Donatello S; Babina IS; Hazelwood LD; Hill AD; Nabi IR; Hopkins AM
    Am J Pathol; 2012 Dec; 181(6):2172-87. PubMed ID: 23031255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ß1 integrin binding phosphorylates ezrin at T567 to activate a lipid raft signalsome driving invadopodia activity and invasion.
    Antelmi E; Cardone RA; Greco MR; Rubino R; Di Sole F; Martino NA; Casavola V; Carcangiu M; Moro L; Reshkin SJ
    PLoS One; 2013; 8(9):e75113. PubMed ID: 24086451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
    Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
    Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.